Evidence map›Paper›PMID 36288990›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Development of Fulminant Type 1 Diabetes Mellitus in the Course of Treatment with Atezolizumab for Hepatocellular Carcinoma.

Munehiro Ikeda, Takashi Tamada, Risa Takebayashi, Gaku Okuno, Iori Yagura, Shohei Nakamori, Taishiro Matsumura, Takuto Yoshioka, Shizuka Kaneko, Naoki Kanda

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Munehiro IkedaDepartment of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan.
Takashi TamadaDepartment of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan.
Risa TakebayashiDepartment of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan.
Gaku OkunoDepartment of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan.
Iori YaguraDepartment of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan.
Shohei NakamoriDepartment of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan.
Taishiro MatsumuraDepartment of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan.
Takuto YoshiokaDepartment of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan.
Shizuka KanekoDepartment of Diabetes/Endocrinology/Metabolism, Takatsuki Red Cross Hospital, Japan.
Naoki KandaDepartment of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan.
Takatsuki Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 71-year-old woman with recurring stage IV hepatocellular carcinoma (HCC) was admitted to our hospital while being treated with atezolizumab and bevacizumab and complained of fatigue, vomiting, and appetite loss. The following were noted on admission: serum glucose level, 633 mg/dL; metabolic acidemia (HCO

Indexed as

Carcinoma, HepatocellularDiabetes Mellitus, Type 1Liver NeoplasmsAgedAntibodies, Monoclonal, HumanizedFemaleHumansNeoplasm Recurrence, LocalAntibodies, Monoclonal, Humanizedatezolizumabatezolizumabfulminant type 1 diabeteshepatocellular carcinoma

Identifiers

PMID36288990
PMCPMC10332974
OpenAlexW4307428718

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.